Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 20 2020 - 8:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
participate in a fireside chat as part of the Piper Sandler 32nd
Annual Virtual Healthcare Conference, being held December 1-3,
2020.
The pre-recorded fireside chat can be accessed beginning
November 23, 2020, from the Investors page of Galera’s website,
investors.galeratx.com, and will remain available for 60 days
following the conference.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing a pipeline of
novel, proprietary therapeutics that have the potential to
transform radiotherapy in cancer. Galera’s lead product candidate
is avasopasem manganese (GC4419), a highly selective small molecule
superoxide dismutase (SOD) mimetic initially being developed for
the reduction of radiation-induced severe oral mucositis (SOM).
Avasopasem is being studied in the Phase 3 ROMAN trial to assess
its ability to reduce the incidence and severity of SOM induced by
radiotherapy in patients with locally advanced head and neck cancer
(HNC), its lead indication. It is also being studied in the EUSOM
Phase 2a multi-center trial in Europe assessing the safety of
avasopasem in patients with HNC undergoing standard-of-care
radiotherapy, the AESOP Phase 2a trial to assess its ability to
reduce the incidence of esophagitis induced by radiotherapy in
patients with lung cancer, and a Phase 2 trial in hospitalized
patients who are critically ill with COVID-19. A pilot Phase 1/2
trial of avasopasem in combination with stereotactic body radiation
therapy (SBRT) in patients with locally advanced pancreatic cancer
has completed enrollment and reported interim results, with
follow-up ongoing. The FDA granted Fast Track and Breakthrough
Therapy designations to avasopasem for the reduction of SOM induced
by radiotherapy. Galera’s second dismutase mimetic product
candidate, GC4711, is being developed specifically to augment the
anti-cancer efficacy of SBRT, and is currently being studied in the
GRECO-1 Phase 1/2 clinical trial in combination with SBRT in
patients with non-small cell lung cancer. Galera is headquartered
in Malvern, PA. For more information, please
visit www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
Jennifer PorcelliSolebury
Trout646-378-2962jporcelli@soleburytrout.com
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024